Written by the Nuvirox Research Team
Key points
- Immunosenescence is the age-related remodelling of the immune system — not simply a decline, but a shift from naive cells that can learn to memory cells that can only repeat.
- The thymus, which trains new T cells, begins shrinking after puberty and is progressively replaced by fat and fibrous tissue.
- One small uncontrolled trial reversed several markers of it in nine men, and the result is far more preliminary than the headlines it generated.
Short answer: your immune system does not simply get weaker with age — it gets less able to recognise anything new, while becoming more inflammatory at baseline. That combination explains a lot: why infections you have met before stay manageable while novel ones hit harder, why vaccine responses fall off in later life, and why chronic low-grade inflammation rises even without an obvious trigger. The organ responsible for the first half of that story starts closing down decades before anyone thinks of themselves as old.
What exactly is immunosenescence?
It is the set of structural and functional changes that accumulate in the immune system with age. The literature increasingly frames it as remodelling rather than decline, because it is not a uniform fade — some functions are lost, some are gained, and the environment the immune cells operate in changes too.
The documented changes span every level: structural change in the bone marrow, thymic involution, fibrosis in lymph nodes with reduction in the number and size of germinal centres, a fall in naive T cells, reduced phagocytic activity of macrophages, lower antibody titres, and an age-related decrease in antigen recognition receptors such as toll-like receptors. Alongside this sits inflammaging — a chronic rise in circulating pro-inflammatory cytokines — which we cover separately in the slow burn behind age-related disease.
Immune aging is layered. No single one of these is the whole story.
Why does the thymus matter so much?
The thymus is where thymocytes mature into naive T cells. Naive T cells are the ones that have not yet met their target antigen — they are the immune system’s capacity to learn something new. Memory T cells handle threats you have already encountered; naive cells handle everything you have not.
Thymic involution during aging reduces the frequency of naive T cells and narrows T cell receptor diversity, so the aged immune system does not recognise new antigens well. Mechanistically, medullary thymic epithelial cells in aged humans show reduced expression of FOXN1, a transcription factor essential for thymic T cell development; lower FOXN1 leads to loss of thymic architecture and reduced secretion of IL-7, a cytokine vital for thymocyte survival and proliferation. Functional thymic tissue is progressively replaced by adipocytes and fibroblasts, which do not support T cell development.
The consequence is a bank account you can spend but not easily refill. This is why a genuinely novel pathogen — and, by the same logic, a vaccine against one — poses a disproportionate problem later in life.
What human studies actually show
Vaccine response declines measurably with age. Reviews of immune aging and vaccination consistently report that age-associated alteration of the immune system produces suboptimal vaccine-induced immunity in older populations, driven by thymic involution, reduced T and B lymphocyte numbers, impaired macrophage activity and lower antibody levels. Both humoral and cellular responses are diminished.
Repeated vaccination is not a simple fix. The same literature notes that while repeated influenza vaccinations can enhance antibody titres and expand CD4+ and CD8+ memory T cells, they may also induce immune tolerance or exhaustion that limits further B cell activation and antibody maturation. Early influenza exposures create long-lasting imprinting that shapes — and can constrain — recognition of new strains.
One trial reversed several markers of immune aging, and it deserves careful framing. The TRIIM trial (Thymus Regeneration, Immunorestoration and Insulin Mitigation), run at Stanford from 2015 to 2017 and published by Fahy and colleagues in Aging Cell in 2019, treated nine putatively healthy men aged 51–65 with recombinant human growth hormone plus DHEA and metformin for one year. The investigators reported regenerated thymic tissue replacing accumulated fat in seven of the nine participants, protective immunological changes, improved risk indices for several age-related diseases, and a mean epigenetic age approximately 1.5 years below baseline — a 2.5-year change relative to no treatment.
The honest counterweight is that TRIIM proves very little on its own. Nine men. No placebo control. No randomisation. All male, all in a narrow age band, all putatively healthy. Independent commentary at the time described it as a small clinical study without placebo controls whose biological effect made it promising — promising being the operative word. It also used growth hormone, which carries its own risk profile; we treat that separately and sceptically in HGH for anti-aging. An expanded trial, TRIIM-X, was registered to test the approach more rigorously.
Study snapshot
| Trial | TRIIM, conducted 2015–2017 |
| Participants | 9 men, aged 51–65 |
| Intervention | rhGH + DHEA + metformin for 1 year |
| Key results | Thymic fat replaced by tissue in 7/9; epigenetic age −1.5 years vs baseline |
| Key limitations | No control group, no randomisation, tiny sample, single sex |
What immunosenescence won’t explain
It will not explain every infection you catch. Exposure, sleep, stress, smoking, nutritional status and vaccination history all matter, and in any given year they matter more than a slow structural trend. If you are suddenly getting sick far more often than you did last year, that is a change worth investigating rather than attributing to age.
It also will not be captured by any consumer test. There is no validated at-home measure of immune age. Naive-to-memory T cell ratios and T cell receptor repertoire diversity are research measurements, not clinical ones, and interpreting them outside a study protocol is not currently possible.
Worth raising with your clinician
Frequent, severe or unusually persistent infections; recurrent shingles; slow wound healing; or new night sweats and unexplained weight loss are not features of ordinary immune aging. They warrant proper evaluation. So does the question of which vaccines are appropriate for your age group — high-dose and adjuvanted formulations exist specifically because standard versions work less well later in life.
What actually helps
Nothing reverses thymic involution outside of experimental protocols. Several things plausibly reduce how much it costs you.
- Vaccination, appropriately chosen. A blunted response is still a response, and age-specific formulations exist for this exact reason.
- Sleep. Sleep deprivation measurably reduces vaccine antibody response in controlled human work and impairs immune function generally.
- Resistance training and adequate protein. Both counter sarcopenia, and muscle loss and immune decline track together in older adults — grip strength is a cheap way to watch that trend.
- Managing chronic inflammation. Inflammaging degrades immune responsiveness, and the modifiable contributors — visceral adiposity, smoking, untreated periodontal disease, poor glycaemic control — are worth addressing on their own merits.
What is conspicuously absent from that list is any supplement with immune-aging outcome data. Correcting a genuine deficiency — zinc, vitamin D, protein — is worthwhile. Beyond sufficiency, the evidence for immune enhancement in healthy older adults is thin, and the marketing considerably outpaces it.
Frequently asked questions
At what age does the immune system start declining?
Thymic involution begins shortly after puberty, which surprises most people. The functional consequences generally do not become obvious until much later, because memory immunity carries a great deal of the load in the intervening decades.
Does immunosenescence mean I should take immune supplements?
Correcting an actual deficiency helps. Beyond that, there is little controlled evidence that supplementation improves immune outcomes in healthy older adults, and none demonstrating an effect on the structural changes described here.
Can you regrow the thymus?
TRIIM reported thymic fat being replaced by functional tissue in seven of nine men using growth hormone plus two other drugs. It was uncontrolled and very small. This is an open research question, not an available intervention.
Is inflammaging the same as immunosenescence?
They are related but distinct. Immunosenescence describes the loss and remodelling of immune function; inflammaging describes the rise in baseline inflammatory signalling. They reinforce each other, which is part of why the combination is hard to untangle.
Why do older adults need different vaccines?
Because standard formulations generate weaker responses in an aged immune system. High-dose and adjuvanted versions are designed to compensate for exactly the deficits described in this article.
From Nuvirox
Why we formulated NAD+ Restore
NAD+ is a metabolic coenzyme, not an immune therapy, and we are not going to suggest otherwise. What the human trials support is narrower and more specific: precursor supplementation reliably raises NAD+, the coenzyme that cellular energy metabolism and repair depend on.
- 500 mg nicotinamide riboside chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek — to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Immunosenescence is real, begins far earlier than most people assume, and is better described as remodelling than as simple decline — the shift from naive to memory cells is what makes new threats disproportionately costly. The mechanistic literature is solid. The interventional literature amounts to one uncontrolled trial in nine men. The fair reading is that the sensible responses are the unglamorous ones: get the vaccines designed for your age group, sleep, keep muscle on, and treat any real change in infection frequency as a medical question rather than an inevitability.
References
- Falahi et al. Immune aging, immunosenescence, and inflammaging: implications for vaccine response in older adults. Health Sci Rep. 2025. DOI: 10.1002/hsr2.71119. PMCID: PMC12286891.
- Fahy GM, Brooke RT, Watson JP, Good Z, Vasanawala SS, Maecker H, Leipold MD, Lin DTS, Kobor MS, Horvath S. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019;18(6):e13028. PMID: 31496122. DOI: 10.1111/acel.13028.
- Targeting inflammation and immunosenescence to improve vaccine responses in the elderly. PMCID: PMC7592394.
- Aging and vaccines: impact of immunosenescence and inflammaging in vaccine response. Front Aging. 2026. DOI: 10.3389/fragi.2026.1797166.
- Immunosenescence: aging and immune system decline. Vaccines. 2024;12(12):1314.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.